Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

Inclusion Criteria

• •Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to randomisation (Visit 2)
• •Current treatment: metformin monotherapy or metformin in any combination with 1 or 2 other OADs including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones (TZDs) all with unchanged dosing for at least 12 weeks prior to randomisation (Visit 2)-metformin: alone or in combination (including fixed combination) must be at least 1000 mg daily
• •HbA1c 7.0-10.0% (both inclusive) by central laboratory analysis
• •BMI (Body Mass Index) no higher than 45.0 kg/m\^2